Oruka Therapeutics, Inc.
NASDAQOruka Therapeutics heads into the back half of August with a striking split: short sellers have been quietly unwinding positions for a month while insiders cashed out in size last week. The most notable development this week was the insider selling cluster. The company's General Counsel Paul Quinlan sold roughly 52,000 shares across five transactions on August 14, taking in just…
ORKA short interest surges 37% in one week to 18.8% of float, driven by heavy short accumulation as biotech faces competition headwinds.
Oruka Therapeutics heads into the back half of August with a striking split: short sellers have been quietly unwinding positions for a month while insiders cashed out in size last week. The most notable development…
ORKA enters July with one of the more charged setups in small-cap biotech: the stock has rallied 63% in a month, short sellers are quietly reducing exposure, and UBS just raised its price target — yet the borrow market…
Snapshot as of 31 Aug 2026
Oruka Therapeutics enters its June 2 earnings event riding a contradictory setup: the stock is down 12% over the past month to $55.01, yet options traders have turned sharply more optimistic than at any point in recent…
Oruka Therapeutics heads into its May 20 earnings call with one of the most aggressive short-interest buildups seen in the small-cap biotech space this year — and a Street that, for now, is pointing firmly in the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ORKA — free to start on ORTEX.
Sign up for free →Open ORKA on ORTEX